• Reported GAAP EPS of $0.22 up 109.44% YoY • Reported revenue of $6.48M down -91.36% YoY • Galapagos expects its year-end 2026 cash and financial investments balance to be in the range of 1.98B to 2.05B, a reduction from prior guidance due to Ouro investment and lower interest income.
Bullish
Galapagos is strategically advancing with a Gilead collaboration and Ouro acquisition, maintaining robust capitalization and achieving a net profit of 14.5M in Q1 2026, reversing the prior year's net loss.
Bearish
Galapagos experienced a significant revenue decline to 6.5M in Q1 2026 and anticipates 125M in cell therapy wind-down costs, contributing to reduced year-end 2026 cash guidance.